December 20, 2012

CLINICAL UPDATE: HELIX BIOPHARMA CORP. COMPLETES ENROLLMENT IN FIRST COHORT AND INITIATES SECOND COHORT IN POLISH PHASE I/II CLINICAL STUDY OF ITS LUNG CANCER DRUG CANDIDATE L-DOS47 (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
innovative drug candidates for the prevention and treatment of cancer, announced the opening of patient
screening for the second dose level cohort in its ongoing Phase I/II clinical safety, tolerability and
preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle in the
three patients enrolled in the first dose level cohort, in which L-DOS47 therapy was well tolerated as
reviewed by the Trial Steering Committee. Patients to be enrolled in the second cohort will receive the next
L-DOS47 dose level as planned in the study protocol: 0.21 micrograms of L-DOS47 per kilogram of patient
body weight.